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patient’s 30-day BP proﬁle was simulated and an individual
correction factor estimated. Each patient’s correction factor was
calculated by dividing the mean of their simulated BP reduction
by the BP reduction achieved with no dosing errors. For each
treatment, the overall correction factor was derived by averaging
the individual correction factors. RESULTS: The much slower
rise in BP after stopping aliskiren, and the high prevalence of
missed doses, led to substantially different correction factors.
CONCLUSIONS: These ﬁndings suggest that once-daily drugs
differ in the extent to which they lower BP in real life, in which
missed doses happen frequently. When differences in correction
factors are applied to drugs with similar efﬁcacy, they can reveal
meaningful (1–3 mmHg systolic BP) differences in real life
effectiveness.
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OBJECTIVES: The purpose of the present study was to investi-
gate, the impact f drug-eluting stents (DES) vs. bare metal stent
(BMS) implantation on the incidence of major adverse cardio-
vascular events in patients with real conditions on the occur-
rence of short-and long term, of stent thrombosis, myocardial
infarction, need for repeat revascularization and clinical symp-
toms and death. METHODS: Since March 1, 2006 to September
31, 2007 a total of 220 consecutive patients with novo lesions
exclusively treated with DES unrestricted use vs. bare metal
stents and 1 year a follow-up. In a cohort of patients with
ischemic disease with indication of PCI (Percutaneous Coronary
Intervention). The measure of effectiveness was compared
in-hospital, 6-month, 1-year outcomes in 220 patients who
underwent PCI using DES or BMS. Major adverse cardiac events
(MACE) included: death cardiac, myocardial infarction (MI),
restenosis angiographic (RA), stent thrombosis, target lesion
revascularisation (TLR) was deﬁned as a repeated revascularisa-
tion procedure (either PCI or coronary bypass surgery), as the
result of restenosis in the stented segment. Deﬁnite stent throm-
bosis was included deﬁned as an acute coronary ischemic event
associated to angiographic documentation of occlusion stent.
Statistical Analysis: continuous variables are presented as
mean+SD and were compared by means of the Student unpaired
t-test. Categorical variables are presented as counts and percent-
ages and compared by means of the Fisher exact test and Sur-
vival curve Kaplan Meier. RESULTS: Age BMS 60.01 +- 9.195
vs. DES 56 +- 9.86 value p = 0.026, diabetes, hypertension,
hypercholesterolaemia, current smoking similar. Both groups
were reasonably well matched for baseline characteristics with
exception age. The Expulsion fraction FEVI BMS 49.64 +- 13%
vs. DES 52.19 +- 11.7%, stents implanted BMS 55.1% vs. DES
42.9% with a medium 1.5 stents for patient. Total MACE
(Major adverse cardiac events): 10 (11.4%) vs. 31(24.2%)
p = 0.018, restenosis and need revascularization lesion target
(TLR) BMS 13 (10.2%) vs. DES 2 (1.6%) p = 0.002, thrombosis
6 (4.7%) vs. 0 p = 0.039, angina 2(1.6%) vs. 6 (6.8%)
p = 0.044, death 10 (7.8%) vs. 0 p = 0.007, test positive for
ischemic 3 (2.3%) vs. 1(1.1%) p = 518, required new revascu-
larization BMS 3 (2.3%) vs. DES 3(3.4%) p = 0.64. The baseline
and procedural characteristics reﬂect the complex patient’s. The
survival free events were BMS 74% vs. DES 88 %, the difference
in major adverse cardiac events was driven by the reduction in
the need for repeat revascularization, deﬁned as TVR in the DES
group. CONCLUSIONS: The lower differential effect in real-
world outcomes, together with increased material use compared
with the difference in major adverse cardiac events was driven by
the reduction in the need for repeat revascularization, deﬁned as
TLR in the DES group.
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OBJECTIVES: To explore the efﬁcacy of Angiotensin Receptor
Blockers (ARBs) in reducing blood pressure (BP) compared to
ACE Inhibitors in a real-world setting. METHODS: We analysed
the records of 16,866 (14,651 ACE Inhibitors and 2,215 ARBs)
adult patients with hypertension who were initiated on the agents
between 1998 and 2006 and who remained on that hypertensive
treatment as monotherapy for the duration of their time in the
database. Anonymised patient data were drawn from the UK
THIN general practice database. Hypertension was deﬁned as a
systolic blood pressure (SBP) reading 140 mmHg or diastolic
BP (DBP) 90 mmHg. RESULTS: In a population means
analysis, at 1 year, mean SBP reductions for patients receiving
ARB therapy reached 13.2 mmHg compared to 11.1 mmHg for
patients receiving ACE Inhibitors. For DBP mean reductions for
patients receiving an ARB reached 7.8 mmHg compared to
6.7 mmHg for patients receiving an ACE Inhibitor. At 2 years,
patients’ mean SBP reductions reached 13.6 mmHg for the ARBs
group and 11.2 mmHg for the ACE Inhibitors group. Similar
results were also observed with DBP at 2 years with patients
receiving ARB treatment reaching reductions of 8.3 mmHg com-
pared to 7.1 mmHg reached by patients receiving an ACE Inhibi-
tor. The comparisons were statistically signiﬁcant (p < 0.001) in
a linear mixed multivariate analysis adjusting for repeated mea-
sures and random practice effects conditioning on baseline blood
pressure, age, diabetes status, hypertensive diagnosis status and
number of other non-hypertensive cardiovascular treatments.
CONCLUSIONS: In a real-world setting, patients receiving
ARBs as monotherapy are observed to achieve greater reductions
in blood pressure compared to those receiving ACE Inhibitors as
monotherapy.
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OBJECTIVES: Among patients at high risk for coronary heart
disease (CHD) LDL-C remains the primary lipid treatment
target. However, HDL-C and triglycerides (TG) have also
emerged as modiﬁable risk factors (RF). This study assessed the
attainment of multiple recommended lipid levels among patients
receiving lipid modifying therapy (LMT). METHODS: A retro-
spective clinical chart review of patients treated in primary care
and hospitals was conducted in Spain. High CHD risk patients
(identiﬁed as patients with CHD/CHD equivalent, or 2+ CHD
RF) who had full lipid panels 12 months pre-LMT (baseline), and
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